To further this point, in the recent Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment trial, the corresponding rates of recurrent ischemia were 39.1%, 22.0%, 15.6%, and 11.9% in patient cohorts that had base Hb levels of <12.0 g/dl, 12.0 to 13.9 g/dl, 14.0 to 15.9 g/dl, and >16.0 g/dl (P = 0.004) [64]. This evidence concerns the gene GSTM1 and ischemia.